Skip to main content
Midas Edge

Curanex Pharmaceuticals Inc

For the period ended Jun 30, 2026. Filed Aug 14, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 14, 2026

CURX$6.21+7.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Changes in Shareholders’ Equity

UNAUDITED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY

Common Stock · Preferred Stock · Common · Additional
Number of Shares · Amount · Number of Shares · Amount · Stock to be issued · Paid in Capital · Accumulated Deficit · Total
Balance at December 31, 202424,000,000$2,4001,000,000$100$200,000$923,309$(622,449)$503,360
Net loss------(137,583)(137,583)
Balance at March 31, 202524,000,000$2,4001,000,000$100$200,000$923,309$(760,032)$365,777
Net loss------(60,346)(60,346)
Balance at June 30, 202524,000,000$2,4001,000,000$100$200,000$923,309$(820,378)$305,431
Balance at December 31, 202528,340,812$2,8341,000,000$100$-$16,063,705$(4,847,555)$11,219,084
Share based compensation24,0002---9,790-9,792
Net loss------(3,150,228)(3,150,228)
Balance at March 31, 202628,364,812$2,8361,000,000$100$-$16,073,495$(7,997,783)$8,078,648
Net loss------(3,290,970)(3,290,970)
Balance at June 30, 202628,364,812$2,8361,000,000$100$-$16,073,495$(11,288,753)$4,787,678
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.